TCAT at SNBTS

We are an established developer and manufacturer of cell therapy products. From two GMP manufacturing facilities, SNBTS have 20 years’ experience delivering autologous and allogeneic products for First in Human, Phase 1 and Phase 2 trials. We also manufacture Master Cell Banks of hESC and iPSC lines. As an NHS establishment, we are uniquely positioned to support academic and other early-stage developers in the translation of their 'proof of concept' stage products into GMP-compatible processes, and to manufacture these products for early-stage clinical trials. We have proven expertise working with somatic cells, pluripotent stem cells and their derivatives, and genetically modified cell therapies. We have extensive in-house QC capacity, specifically developed for ATMPs, including endotoxin and sterility, cell identify and function, and stability studies. In parallel, TCAT has its own internal R&D function focused on developing platform solutions common across different product groups to facilitate scale-up and scale-out of safe and effective ATMPs. Part of SNBTS's 2030 Vision is to transform health through blood, tissue and advanced therapies.